1. Aigbogun MS, Liu S, Kamat SA, Sapin C, Duhig AM, Citrome L. Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. Clin Outcomes Res 2018; 10: 443–56.
2.
Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: Absolute risk increase and number needed to harm. J Clin Psychopharmacol 2017; 37: 138–147.
3.
Correll CU, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C. et al. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies. Schizophr Res 2016; 174: 82–92.
4.
Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: A 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015; 172: 870–880.
5.
Fleischhacker WW, Hobart M, Ouyang J, Forbes A, Pfister S, McQuade RD et al. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2016; 20: 11–21.
6.
Forbes A, Hobart M, Ouyang J, Shi L, Pfister S, Hakala M. A Long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as maintenance treatment in adults with schizophrenia. Int J Neuropsychopharmacol 2018; 21: 433–441.
7.
Frampton JE. Brexpiprazole: A review in schizophrenia. Drugs 2019; 79: 189–200.
8.
Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol 2017; 7: 29–41.
9.
Gałązka-Sobotka M, Gryglewicz J, Gierczyński J, Wrona W, Karczewicz E, Zalewska H. et al. Schizofrenia – analiza kosztów społecznych i ekonomicznych. Psychiatria 2015; 12: 17–46.
10.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. The Lancet 2019; 394: 939–951.
11.
Ishigooka J, Iwashita S, Higashi K, Liew EL, Tadori Y. Pharmacokinetics and safety of brexpiprazole following multiple-dose administration to Japanese patients with schizophrenia. J Clin. Pharmacol 2018; 58: 74–80.
12.
Ishigooka J, Iwashita S, Tadori Y. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study: Brexpiprazole for schizophrenia. Psychiatry Clin Neurosci 2018; 72: 692–700. (b)
13.
Ishigooka J, Iwashita S, Tadori Y. Long‐term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52‐week, open‐label study. Psychiatry Clin Neurosci 2018; 72: 445–53. (c)
14.
Jarema M, Wichniak A. Long-acting aripiprazole in the treatment of schizophrenia; practical aspects. Pharmacother Psychiatry Neurol 2016; 32:145–56.
15.
Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD et al. Schizophrenia. Nat Rev Dis Primer 2015; 1: 15067.
16.
Kane JM, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C et al. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res 2016; 174: 93–98.
17.
Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 2015; 164: 127–135.
18.
Kikuchi T, Maeda K, Suzuki M, Hirose T, Futamura T, McQuade RD. Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole. Neuropsychopharmacol Rep 2021; 41: 134–143.
19.
Kishi T, Ikuta T, Matsuda Y, Sakuma K, Iwata N. Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis. Psychopharmacology (Berl.) 2020; 237: 1459–70.
20.
Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T. et al. Brexpiprazole I: In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014; 350: 589–604.
21.
Marder SR, Eriksson H, Zhao Y, Hobart M. Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia. Acta Neuropsychiatr 2020; 32: 153–158.
22.
Marder SR, Hakala MJ, Josiassen MK, Zhang P, Ouyang J, Weiller E et al. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. Acta Neuropsychiatr 2017; 29: 278–90.
23.
Mauri MC, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I et al. Clinical pharmacokinetics of atypical antipsychotics: An update. Clin. Pharmacokinet. 2018; 57: 1493–528.
24.
Nucifora FC, Woznica E, Lee BJ, Cascella N, Sawa A. Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. Neurobiol Dis 2019; 131: 104257.
25.
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 2020; 7: 64–77.
26.
Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2: e141.
27.
Schneider-Thoma J, Chalkou K, Dörries C, Bighelli I, Ceraso A, Huhn M et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. The Lancet 2022; 399: 824–36.
28.
Weiss C, Weiller E, Baker RA, Duffy RA, Gwin KK, Zhang P. et al. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies. Int Clin Psychopharmacol 2018; 33: 255–260.
